Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Brivaracetam

An antiepileptic drug that binds the synaptic vesicle protein SV2A, modulating neurotransmitter release: a close relative of levetiracetam, it was approved in Europe and the United States in 2016 for focal seizures. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.

Did you know?It came from a research programme that screened about 12,000 molecules to find an SV2A ligand with higher affinity than levetiracetam: the chosen one binds 15 to 30 times more tightly.

BrivaracetamGo to the active ingredient →
BrivaracetamActive ingredientBrivaracetamCat. No. P-B111-001CAS 357336-20-0

EDQM standards 6

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.